Long-term efficacy, safety, and patient-reported outcomes of oveporexton in adults with narcolepsy type 1
Abstract
Oveporexton, a selective oral orexin-2 receptor agonist, represents a targeted therapeutic approach for narcolepsy type 1 (NT1). Phase 2 and 3 trials demonstrate significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy, alongside potential cognitive benefits. However, available data are limited to relatively short treatment periods, and the durability of these effects – as well as their impact on daily functioning – remains to be clarified. Long-term studies will need to jointly evaluate efficacy, cognitive function, quality of life, daily and occupational functioning, treatment adherence, and safety. These data will help determine whether the short-term benefits are sustained over the long term and translate into a clinically significant improvement in the lives of patients with NT1.